Search research articles
Contact Us
Filters
Showing results (221-230 of 267) with videos related to
Page
of 27
Sort By:
Scientific Reports
|
May 4, 2022
Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study
Pierre Hausfater, David Boutolleau, Karine Lacombe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 26, 2020
Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
Andrew Atkinson, Marcel Zwahlen, Diana Barger, et al.
The Lancet. Infectious Diseases
|
May 26, 2024
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design
Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 9, 2025
Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trial
Béatrice Bercot, Lambert Assoumou, François Caméléna, et al.
The Lancet. HIV
|
May 15, 2026
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial
Roland Landman, Lambert Assoumou, Sidonie Lambert-Niclot, et al.
AIDS (London, England)
|
November 27, 2014
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
Catia Marzolini, Caroline Sabin, François Raffi, et al.
BMC Infectious Diseases
|
September 27, 2025
High prevalence of bacterial STI, anal HPV, cytological abnormalities and anal lesions among MSM in Togo, 2021: a baseline analysis of the ANRS I MIE 12,400/DepIST-H cohort
Valentine M Ferré, Arnold J Sadio, Fifonsi A Gbeasor-Komlanvi, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
March 15, 2024
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022
Romain Palich, Andrés Arias-Rodríguez, Martin Duracinsky, et al.
Fundamental & Clinical Pharmacology
|
April 20, 2021
Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review
Nathalie Gault, Marina Esposito-Farèse, Matthieu Revest, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial
Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 267) with videos related to
Sort By:
Page
of 27
Scientific Reports
|
May 4, 2022
Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study
Pierre Hausfater, David Boutolleau, Karine Lacombe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 26, 2020
Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
Andrew Atkinson, Marcel Zwahlen, Diana Barger, et al.
The Lancet. Infectious Diseases
|
May 26, 2024
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design
Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 9, 2025
Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trial
Béatrice Bercot, Lambert Assoumou, François Caméléna, et al.
The Lancet. HIV
|
May 15, 2026
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial
Roland Landman, Lambert Assoumou, Sidonie Lambert-Niclot, et al.
AIDS (London, England)
|
November 27, 2014
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
Catia Marzolini, Caroline Sabin, François Raffi, et al.
BMC Infectious Diseases
|
September 27, 2025
High prevalence of bacterial STI, anal HPV, cytological abnormalities and anal lesions among MSM in Togo, 2021: a baseline analysis of the ANRS I MIE 12,400/DepIST-H cohort
Valentine M Ferré, Arnold J Sadio, Fifonsi A Gbeasor-Komlanvi, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
March 15, 2024
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022
Romain Palich, Andrés Arias-Rodríguez, Martin Duracinsky, et al.
Fundamental & Clinical Pharmacology
|
April 20, 2021
Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review
Nathalie Gault, Marina Esposito-Farèse, Matthieu Revest, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial
Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Page
of 27